Medetomidine: The New Xylazine? What Laboratories Shoul...
At a recent conference, a forensic toxicologist mentions something you h...
Establishing QC Ranges for New Assays: A Practical Meth...
When Good Assays Fail QC A laboratory validates a new immunoassay, runs ...
Nitazenes: What Labs Need to Know About the Next Wave o...
A forensic toxicologist runs a comprehensive opioid panel on a suspected...
Matrix Effects in LC-MS/MS: A Troubleshooting Guide for...
The instrument passes system suitability. Calibrators look perfect. Your...
Designer Benzodiazepines: The Hidden Challenge in Toxic...
A forensic toxicologist calls with a familiar problem: three overdose de...
Fentanyl Analogues in 2026: A Laboratory Detection Guide
A medical examiner calls with a case that doesn’t add up. The immunoas...
Is Your QC Helping or Hurting Your TDM Patients?
When “Close Enough” Isn’t Good Enough: The Risk to Patient...
Case Study: How UTAK Manufactured the First-Ever Xylazi...
As the opioid epidemic has evolved, a new threat has emerged in the form...
Checklist: Is Your Lab Ready for the FDA’s New Requirem...
To help your lab prioritize its compliance strategy, use this checklist ...
Find Us on Social
